Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Anoro Ellipta contains two molecules specifically selected for their long duration of action, enabling once-daily dosing1-8
Anoro Ellipta contains umeclidinium (a LAMA) and vilanterol (a LABA). These molecules work together to promote bronchodilation: the LAMA blocks bronchoconstriction and the LABA stimulates bronchodilation.1
See how the molecules work
The LAMA and LABA in Anoro Ellipta work together to promote bronchodilation
LAMA - Umeclidinium
LABA - Vilanterol
Indication: Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.
Dosing: The recommended (and maximum) dose is one inhalation of ANORO ELLIPTA (UMEC/VI 55/22 micrograms) once daily. The dose should be administered at the same time of the day each day to maintain bronchodilation.
Please refer to the SmPC for further information prior to prescribing.
References
- Anoro Ellipta SmPC
- Maleki-Yazdi M et al. Adv Ther 2016;33:2188–2199.
- Feldman G et al. Int J Chron Obstruct Pulmon Dis 2016;11:719–730.
- Laine DI. Exp Rev Clin Pharmacol 2010;3:43–53.
- Laine DI. J Med Chem 2009;52:2493–2505.
- Slack RJ et al. J Pharmacol Exp Ther 2013;344:218–230
- Hanania N et al. Chest 2012;142:119–127.
- Kempsford R et al. Pulm Pharmacol Ther 2013;26(2):256–264.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
© 2021 GSK group of companies or its licensor.
ANORO was developed in collaboration with INNOVIVA.
Trademarks are owned by or licensed to the GSK group of companies.
PM-GB-UCV-WCNT-210001 May 2021
